The Ledger

ABBV

Abbvie IncHealth Careinsider_universe

Last close $253.95Jun 28, 2026

Day +0.24%

Currently held

Agent 20 — SIR Price/Volumelong
7 sh @ $229.96 · stop $214.05
+$177.03 unrealized

Everything we've seen

·Jun 29, 3:49 PMstreamnews
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
·Jun 29, 3:49 PMstreamnews
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
·Jun 29, 3:49 PMstreamnews
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
·Jun 29, 3:49 PMstreamnews
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
·Jun 29, 3:49 PMstreamnews
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
·Jun 29, 3:49 PMstreamnews
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
·Jun 29, 3:49 PMstreamnews
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
·Jun 29, 3:49 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
·Jun 29, 3:49 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
·Jun 29, 3:34 PMstreamnews
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
·Jun 29, 3:34 PMstreamnews
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
·Jun 29, 3:34 PMstreamnews
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
·Jun 29, 3:34 PMstreamnews
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
·Jun 29, 3:34 PMstreamnews
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
·Jun 29, 3:34 PMstreamnews
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
·Jun 29, 3:34 PMstreamnews
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
·Jun 29, 3:34 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
·Jun 29, 3:34 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
·Jun 29, 3:19 PMstreamnews
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
·Jun 29, 3:19 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
·Jun 29, 3:19 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
·Jun 29, 3:19 PMstreamnews
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
·Jun 29, 3:19 PMstreamnews
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
·Jun 29, 3:19 PMstreamnews
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
·Jun 29, 3:19 PMstreamnews
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
·Jun 29, 3:19 PMstreamnews
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
·Jun 29, 3:19 PMstreamnews
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
·Jun 29, 3:05 PMstreamnews
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
·Jun 29, 3:05 PMstreamnews
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
·Jun 29, 3:05 PMstreamnews
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
·Jun 29, 3:05 PMstreamnews
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
·Jun 29, 3:05 PMstreamnews
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
·Jun 29, 3:05 PMstreamnews
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
·Jun 29, 3:05 PMstreamnews
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
·Jun 29, 3:05 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
·Jun 29, 3:05 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
·Jun 29, 2:49 PMstreamnews
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
·Jun 29, 2:49 PMstreamnews
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
·Jun 29, 2:49 PMstreamnews
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
·Jun 29, 2:49 PMstreamnews
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
·Jun 29, 2:49 PMstreamnews
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
·Jun 29, 2:49 PMstreamnews
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
·Jun 29, 2:49 PMstreamnews
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
·Jun 29, 2:49 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
·Jun 29, 2:49 PMstreamnews
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
❖Jun 29, 1:14 PMnewsvia finnhub
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check
If you are trying to figure out whether AbbVie stock still offers value after its recent performance, starting with a clear view of price versus fundamentals is essential. AbbVie has recently traded at US$253.35, with returns of 10.1% over 7 days, 16.4% over 30 days, 10.5% year to date, 40.9% over 1 year, 109.0% over 3 years and 165.3% over 5 years, which has naturally focused attention on whether the current price fairly reflects the business. Recent headlines have focused on AbbVie’s...
❖Jun 29, 12:08 PMnewsvia finnhub
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe
AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...
❖Jun 29, 12:03 PMnewsvia finnhub
3 No-Brainer Dividend Stocks to Buy Right Now
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
❖Jun 29, 11:41 AMnewsvia finnhub
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
In the past five years, this top healthcare stock has risen by close to 130%.
❖Jun 29, 11:22 AMnewsvia finnhub
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
❖Jun 29, 11:21 AMnewsvia finnhub
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?
❖Jun 29, 11:17 AMnewsvia finnhub
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
❖Jun 29, 11:16 AMnewsvia finnhub
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?
❖Jun 29, 11:10 AMnewsvia finnhub
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
❖Jun 29, 10:19 AMnewsvia finnhub
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
❖Jun 29, 10:02 AMnewsvia finnhub
2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
!Jun 29, 9:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 29, 9:27 AMnewsvia finnhub
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
!Jun 29, 7:06 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 29, 7:05 AMnewsvia finnhub
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. REGENXBIO will receive $100 million from AbbVie for this milestone.
❖Jun 29, 3:10 AMnewsvia finnhub
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
❖Jun 29, 3:00 AMnewsvia finnhub
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The final European Commission decision is expected in the coming months. If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitili
❖Jun 28, 10:01 AMnewsvia finnhub
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
❖Jun 28, 4:45 AMnewsvia finnhub
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a Strong Buy.
❖Jun 27, 8:07 PMnewsvia finnhub
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
❖Jun 27, 3:21 PMnewsvia finnhub
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
❖Jun 27, 2:05 PMnewsvia finnhub
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
❖Jun 27, 2:28 AMnewsvia finnhub
Best Dividend Aristocrats: June 2026
Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.
❖Jun 26, 9:00 PMnewsvia finnhub
Red-alert heatwaves are becoming Europe's new normal. Investors are paying attention
Temperature records were smashed across Europe this week, prompting several countries across the continent to issued high-level warnings about danger to life.
❖Jun 26, 7:35 PMnewsvia finnhub
This Week's Market Wrap: AI Memory Shock, Crude Cracks, And Data Boxes In The Fed
Micron delivered a blowout quarter & reinforced strength of AI-driven memory demand, but same surge in memory prices pressured Apple, Microsoft, Amazon & other mega-cap technology names.
❖Jun 26, 4:50 PMnewsvia finnhub
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg PFS and Pen are approved
❖Jun 26, 1:49 PMnewsvia finnhub
Lilly, J&J and AbbVie Hit New Highs
Lilly, AbbVie and J&J extend winning streaks.
❖Jun 26, 1:01 PMnewsvia finnhub
Why BMO's Siegerman says Merck is a top healthcare stock pick
CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.
❖Jun 26, 12:54 PMnewsvia finnhub
AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis
AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis
!Jun 26, 12:49 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 12:03 PMnewsvia finnhub
AbbVie Stock's Growth Story Has One Question Mark
The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.
!Jun 26, 11:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:48 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 9:52 AMnewsvia finnhub
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy
Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy's Gourmet Bakery.
!Jun 26, 9:50 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:17 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 8:00 AMnewsvia finnhub
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
!Jun 26, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 7:03 AMnewsvia finnhub
The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?
What does retirement look like for someone who genuinely has no desire to leave home? No snowbird condo in Florida. No Viking river cruises. No RV parked outside Yellowstone. Just Chicago. The Cubs in the summer, the museums when the weather turns, dinner at the neighborhood Italian restaurant, church on Sunday, and grandchildren across town ... The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?
❖Jun 26, 5:22 AMnewsvia finnhub
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Jazz Pharmaceuticals' shares are in the distribution phase because Zepzelca failed to show a survival benefit over irinotecan. See why JAZZ stock is downgraded to hold.
❖Jun 26, 4:20 AMnewsvia finnhub
High Income Outpaces Mega-Cap Tech In Return/Risk Terms
Stocks with above-average dividend yields often represent mature businesses with resilient earnings and disciplined management. Read more here.
❖Jun 25, 9:10 PMnewsvia finnhub
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?
Earlier this week, AbbVie reported European Commission approvals extending Skyrizi to children with moderate to severe plaque psoriasis and making Maviret the only therapy cleared in the EU for both acute and chronic hepatitis C infection from age three. These label expansions broaden AbbVie’s reach in immunology and virology by opening earlier treatment windows and adding pediatric populations in high-need diseases. We’ll now explore how Skyrizi’s new pediatric indication and Maviret’s...
!Jun 25, 5:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 5:15 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
!Jun 25, 5:06 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:32 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:21 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:48 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:20 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 2:02 PMnewsvia finnhub
S&P 500 heads for losing week, chip stocks add to their losses on Friday: Live updates
OpenAI is reportedly considering delaying its IPO and as a sell-off in tech gathered pace.
!Jun 25, 1:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 1:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 11:55 AMnewsvia finnhub
Formula Wellness Earns Top 50 Status for 2026 from Allergan Aesthetics
Formula Wellness, a leader in integrated longevity and aesthetic medicine, announced that it has earned Top 50 Status for 2026 from Allergan Aesthetics, an AbbVie company and the makers of Botox®. The recognition honors Formula Wellness's ongoing commitment to the Allergan Aesthetics portfolio and places the practice among the program's highest-performing partners, reflecting a year of rapid growth as one of the fastest-growing integrated wellness and aesthetics platforms in the U.S.
❖Jun 25, 10:13 AMnewsvia finnhub
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
!Jun 25, 9:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 8:15 AMnewsvia finnhub
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
!Jun 25, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 24, 11:35 PMnewsvia finnhub
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
AbbVie Inc. (NYSE:ABBV) is included among the Top 10 Blue Chip Stocks with Growing Dividends. On June 23, Canaccord raised its price recommendation on AbbVie Inc. (NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie’s announced acquisition of Apogee Therapeutics (APGE). Canaccord said the […]
!Jun 24, 6:05 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 5:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 24, 4:33 PMnewsvia finnhub
Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut
I hit the buy button on AbbVie (NYSE:ABBV) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase headlines around sticky 4.2% inflation and a softening jobs picture, I keep adding shares of a cash machine that does not care which way ... Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut
❖Jun 24, 3:32 PMnewsvia finnhub
The Number That Could Test AbbVie Stock
AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.
❖Jun 24, 2:15 PMnewsvia finnhub
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a
❖Jun 24, 11:38 AMnewsvia finnhub
The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari
Most retirees shop for dividend portfolios the same way people shop for cars: they focus on what they get today. A portfolio yielding $90,000 a year feels like the retirement equivalent of driving a Ferrari off the lot. Another portfolio paying only $45,000 can look more like a dependable Honda. The mistake is assuming the race ... The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari
❖Jun 24, 10:02 AMnewsvia finnhub
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
❖Jun 24, 9:32 AMnewsvia finnhub
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
ABBV gains EU approval for Skyrizi in pediatric plaque psoriasis, expanding reach in younger patients with a new weight-based dosing option.
❖Jun 24, 9:13 AMnewsvia finnhub
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
❖Jun 24, 8:00 AMnewsvia finnhub
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in women businessowners.
❖Jun 24, 7:55 AMnewsvia finnhub
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
❖Jun 24, 7:46 AMnewsvia finnhub
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 15.79%. Currently, AbbVie has a market capitalization of $417.60 billion.
✓Jun 22, 6:06 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] From 2026-06-08 through 2026-06-18, ABBV carved out a tight consolidation cluster between $216.49 and $227.73 on subdued, declining volume (ranging 4.1M–5.9M, well beneath the 20-day ADV of 5.5M), with the last session of that cluster (2026-06-18, close $216.49, volume 9.6M) a high-volume down-day that appeared to flush weak holders. Today's bar (2026-06-22) then broke decisively above the entire cluster with a +6.22% gain to $229.96 on 13.1M shares — a volume z-score of +5.74 — representing roughly 2.4× the trailing ADV and the single heaviest volume day in the 20-day window by a wide margin. Under the SIR 2-D framework, this trajectory — a path that compresses horizontally (volume contracting while price idles), followed by a sharp up-and-right leap — is the textbook cluster_break_up signal, suggesting fresh demand decisively absorbed the available float at higher prices. Risks: The signal rests on a single extraordinary bar (2026-06-22), and SIR methodology cautions that one-bar breakouts without subsequent confirming sessions carry elevated failure risk — a close back below the cluster midpoint (~$222–$224) on expanding volume in the next 1–3 sessions would strongly indicate a false break and invalidate the read. Additionally, the macro context (5-year inflation expectations 1.5σ below trend as of 2026-06-18) could weigh on risk appetite broadly, and if today's catalyst (likely a binary event such as clinical data or guidance) proves transient or is revised, the volume spike could recast as exhaustion rather than accumulation.
?Jun 22, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 4.68% today, a meaningful move indicating real institutional flow and conviction. With 330 minutes remaining (well into the session but still substantial time before the 3:45 PM cutoff), there is room for continuation. No news catalyst is identified, which is not unusual — large pharmaceutical names frequently move on options activity, analyst upgrades, or pipeline-related flow that doesn't immediately surface in headlines. The macro context (5Y inflation breakevens 1.5σ below trend) is modestly relevant for healthcare/pharma in that a lower inflation expectations environment is generally supportive of defensive/dividend-paying sectors like large-cap pharma, which ABBV represents. No reversal pattern is described — the move appears directional rather than a morning gap fade. The absence of a clear catalyst and the already-extended 4.68% move introduce some fade risk as profit-takers may emerge, but the bounded risk profile of the setup (tight stop, fixed target, forced flatten) favors taking the trade at modest probability. Assigning 0.54 — slight lean toward continuation without strong confirmation signals.
?Jun 8, 1:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 2.55% intraday with no headline catalyst visible, suggesting either broad sector rotation or institutional distribution rather than a news-driven spike that might reverse quickly. The macro context shows a compressed yield curve (T10Y2Y at 2.5σ below trend), which is modestly supportive of defensives like pharma/biotech in a bear-flattening environment — this creates a slight headwind against further downside continuation, as defensive names can attract dip buyers when rates are flattening. However, a 2.55% move represents meaningful selling flow and without a reversal signal or clear exhaustion pattern noted, momentum modestly favors continuation. With 135 minutes remaining there is ample time for the move to extend. No reversal catalyst is present. The yield curve context provides a mild dampening effect on conviction, keeping this at low-probability continuation rather than a strong setup. Assigning modest continuation probability just above the threshold given the defensive sector tailwind partially offsetting the momentum signal.
?Jun 5, 2:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 1.88% on the day — a meaningful move showing real buying conviction, though not quite into the 2-5% range that would signal a more aggressive trend day. No news catalyst is identifiable, suggesting this is either sector rotation or institutional accumulation rather than a headline-driven spike prone to quick reversal. The macro context (T10Y2Y at 0.42, 1.9σ below trend) is modestly supportive for defensives like ABBV — a flattening/slightly inverted curve environment historically favors large-cap healthcare/defensive names as money rotates away from financials and cyclicals. With 89 minutes remaining there is ample time for continuation before the 3:45 PM cutoff. The main drag on conviction is the absence of any identifiable catalyst and no volume data to confirm institutional follow-through. The move is real but not exceptional, so I assign a modest continuation probability above the 0.5 threshold — enough to warrant a position given bounded risk parameters, but not a high-conviction setup.
?Jun 2, 9:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 2.20% with 375 minutes remaining (roughly 6+ hours of trading time, indicating this is early-to-mid session). The move is meaningful and suggests real institutional selling pressure. No headlines are available to explain the move, but absence of news does not disqualify momentum — large moves without obvious catalysts often reflect pre-positioned institutional flow or sector rotation rather than retail reaction to news. The macro context shows T10Y2Y at 0.42, notably 2.0σ below its 24-month trend, which is a mild bear-flattening signal that favors defensives like ABBV in theory — however, this is a double-edged dynamic: defensives can also see profit-taking when yield curves compress as investors rotate. With ample time remaining, if selling flow is sustained, there is room for further downside toward the +3% profit target from current levels (~$206.55). No reversal pattern is evident from the data provided. Balancing the modest move magnitude (2.2% — real but not extreme), no supportive newsflow, mild macro tailwind that is ambiguous for ABBV specifically, and meaningful time remaining, continuation probability is assessed at 0.52 — a modest lean toward continuation of the down move without strong conviction.
?May 22, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.28% intraday with no attributable headline, suggesting real institutional flow rather than a news pop that could fade on profit-taking. With 315 minutes remaining (roughly 5+ hours, implying this is early-to-mid session), there is meaningful time for the move to extend toward the close. No reversal signals are present in the data provided. The macro context (T10Y3M at +2.2σ above trend) is somewhat cautionary for risk assets broadly, but ABBV is a defensive large-cap pharma/biotech name that is not directly in the Banks or Recession-sensitive sectors flagged by the yield curve signal — so macro headwind is modest. Absence of news is not a disqualifier per the trading framework. The move is in the lower half of the 2-5% meaningful-flow range, suggesting conviction is present but not overwhelming. Overall, momentum favors modest continuation with no strong fade catalyst, warranting a slight lean toward upside continuation.
?May 19, 2:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.23% with 95 minutes remaining, representing meaningful intraday conviction and real flow. No news headlines are present, but absence of news is not disqualifying — this move reflects actual positioning. The macro context flags elevated 10Y breakeven inflation (2.48, 2.4σ above trend), which is a mild headwind for long-duration sensitive sectors; however, ABBV as a large-cap pharma/dividend name has moderate but not extreme duration sensitivity. The move magnitude (2.23%) is at the lower end of the 'meaningful' threshold, suggesting some but not overwhelming conviction. With 95 minutes remaining there is adequate time for continuation but also time for a partial fade. No reversal signals are evident from the data provided. On balance, momentum leans modestly toward continuation into the close, though the elevated inflation expectations environment introduces some drag. Assigning a modest continuation probability above 0.5 given the directional move and sufficient remaining session time, tempered by macro headwinds.
?May 19, 12:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.62% intraday with no attributable headline, suggesting the move is flow/positioning-driven rather than news-catalyzed. That cuts both ways — no catalyst to fade, but also no fundamental anchor to sustain it. With 190 minutes remaining there is meaningful time for continuation, but the macro context is a mild headwind: 10Y inflation breakevens running 2.4σ above trend typically pressures long-duration sensitive sectors, and large-cap pharma/biotech like ABBV carries some duration sensitivity given its dividend yield and defensive characteristics. No reversal pattern is evident from the data provided, and the move size (2.62%) is real but not extreme. Overall, this is a modest momentum setup with no strong reason to fade — probability sits just above neutral.
?May 19, 10:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.03% with ~305 minutes remaining, suggesting meaningful institutional flow with ample time for continuation. No headlines available to explain the move, which is common for flow-driven intraday setups. The macro context shows elevated inflation expectations (T10YIE 2.4σ above trend), which is modestly unfavorable for long-duration equities but ABBV is a defensive healthcare/pharma name with relatively low duration sensitivity — its dividend yield and defensive characteristics may actually attract rotation in a risk-off or inflation-hedging environment. The absence of a clear catalyst cuts both ways: no news means no obvious fade trigger, but also no fundamental anchor sustaining the move. A 2% move represents real conviction, and with over 5 hours remaining, momentum has room to run. No reversal signal is evident. Setting probability modestly above baseline given the size of move, time remaining, and defensive sector profile partially insulating from macro headwinds.
✓May 14, 1:08 PMdecisionacted
Agent 7 — Day Trader — decide: buy
ABBV is up 1.12% today, a modest but real move suggesting some directional flow. No headlines are present to explain the move, which is common and not disqualifying. The macro context flags elevated 5-year inflation expectations (T5YIE at 2.5σ above trend), which is more relevant to Gold, Energy, and TIPS sectors — ABBV as a large-cap pharma/biotech name is largely insulated from this inflationary signal, neither helped nor hurt materially. With 157 minutes remaining, there is ample time for continuation if momentum holds. However, the move is only 1.12%, which is below the threshold where strong conviction is clearly evident. No sector tailwind, no news catalyst, and no reversal signal visible — this is a borderline read. The asymmetric risk structure (tight -1.5% stop, +3% target, forced flatten) favors taking the trade at the margin. Assigning a slight lean toward continuation given time remaining and no contrary evidence.
▢May 13, 8:00 PMjournal
Agent 7 — Day Trader opened long 9 @ $210.83
▣May 13, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 9 @ $210.94 (+$0.94)
EOD forced close — day trader never carries overnight
?May 13, 9:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.51% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a thin-volume intraday spike. The macro context highlights elevated inflation expectations (T5YIE at 2.5σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 375 minutes remaining there is ample time for reversion, but without a clear catalyst, mean-reversion risk is roughly equal to continuation probability.
?May 13, 9:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.51% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated 5-year inflation expectations (2.69, 2.5σ above trend), which primarily benefits Gold, Energy, and TIPS sectors — not pharma/biotech — providing no tailwind for ABBV continuation. With 390 minutes remaining (a full trading day essentially), there is time for mean reversion, and without a clear fundamental catalyst, the gap-and-hold thesis is weak.
?May 13, 9:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.51% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this reflects genuine fundamental buying or a thin-volume gap. The macro context (elevated 5-year inflation breakevens at 2.5σ above trend) is not a typical tailwind for large-cap pharma like ABBV, which tends to be more rate-sensitive than inflation-sensitive. With 405 minutes remaining and no clear catalyst, mean-reversion risk is meaningful and the setup does not meet the threshold for a high-confidence continuation.
?May 12, 3:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.60% today with no identifiable catalyst from recent headlines, suggesting this may be a gap-up or broad market lift rather than a news-driven continuation setup. The macro context (elevated inflation expectations) is not particularly bullish for large-cap pharma like ABBV. With only 30 minutes remaining until the forced close cutoff, there is limited time for meaningful additional price discovery, and late-session mean reversion is a real risk on an unexplained move of this magnitude.
?May 12, 3:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.73% with no accompanying news headlines to explain the move, making it difficult to attribute the gain to a clear fundamental catalyst that would drive further continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma/biotech name like ABBV. With only 45 minutes remaining until the forced close, there is limited time for meaningful additional upside even if the move were catalyst-driven, and without a clear story the risk of mean reversion or profit-taking into the close is elevated.
?May 12, 2:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.84% with no identifiable news catalyst in the headlines, suggesting the move may be driven by sector rotation, options activity, or thin volume rather than a fundamental event. The macro context (elevated 5Y inflation expectations) is not directly supportive of a healthcare/pharma name like ABBV. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst, mean reversion or consolidation is equally plausible.
?May 12, 2:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.16% today with no identifiable headline catalyst in the last 24 hours, making it difficult to assess whether this move has fundamental support or is driven by technical flows or sector rotation. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a clear tailwind for healthcare/pharma names like ABBV. With 74 minutes remaining, there is insufficient catalyst clarity to confidently expect continuation, and large gap-up moves without news often see partial mean reversion into the close.
?May 12, 2:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up ~2.87% with no identifiable news catalyst in the last 24 hours, suggesting the move may be gap-driven or sector-rotation-related rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma name like ABBV. With 90 minutes remaining and no clear continuation catalyst, mean reversion or consolidation near current levels is equally plausible as further upside.
?May 12, 2:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 3.19% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this is a sustainable directional trend or a gap/spike that may fade. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a healthcare/pharma name. With 105 minutes remaining and no clear fundamental catalyst, mean-reversion pressure after a ~3% intraday move is a real risk, and the lack of headlines leaves the driver ambiguous.
?May 12, 1:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has made a strong 3.62% move with 135 minutes remaining, but there are no identifiable catalysts in recent headlines to explain or sustain the move, suggesting it may be a gap or block-driven event rather than a news-driven continuation. The macro context (elevated 5-year inflation expectations) is not directly supportive of large-cap pharma like ABBV, which is not a typical beneficiary of inflation-reactive sectors. Without a clear fundamental driver, mean-reversion or consolidation into the close is at least as likely as continuation, warranting an uncertain stance.
?May 12, 1:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 3.64% with no identifiable catalyst in recent headlines, suggesting this may be a gap-driven move without fresh fundamental support to sustain momentum into the close. The macro context (elevated 5Y inflation expectations) does not specifically benefit healthcare/pharma names like ABBV. With 150 minutes remaining, there is time for the move to extend, but absent a clear news catalyst and given the tendency for large gap-up moves without catalysts to partially fade mid-session, continuation is uncertain.
?May 12, 1:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 4% intraday with no accompanying headlines or identifiable catalyst visible in the data, suggesting this may be a gap or spike move without clear fundamental support for continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a healthcare/pharma name like ABBV. With 165 minutes remaining there is time for continuation, but absent a clear catalyst, mean-reversion or consolidation is equally plausible, keeping conviction low.
?May 12, 12:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.40% today with no accompanying news catalysts visible, suggesting this could be a gap or technical move without a clear fundamental driver sustaining it. The macro context (elevated 5-year inflation expectations) is more relevant to commodities and TIPS sectors than healthcare/pharma, providing no directional tailwind. With 180 minutes remaining there is time for movement, but absent a catalyst and with a sizable move already priced in, mean reversion risk is meaningful.
?May 12, 12:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has already moved 3.19% intraday with no identifiable headline catalyst, suggesting this may be a gap-and-fade or thin-volume spike rather than a news-driven momentum move. The macro context (elevated inflation expectations via T5YIE) is not particularly favorable or unfavorable for a large-cap pharma/biotech like ABBV. With 195 minutes remaining and no clear catalyst to sustain the move, mean reversion is a plausible outcome, making continuation uncertain.
?May 12, 12:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.93% with no accompanying headlines or identifiable catalyst, suggesting the move may be driven by broader market sentiment or a gap that has already largely played out. The macro context highlights elevated inflation expectations (T5YIE 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 210 minutes remaining there is time for the move to extend, but without a clear fundamental catalyst, mean reversion or consolidation is equally plausible.
?May 12, 12:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.27% with no identifiable news catalyst in the recent headlines, suggesting this may be a gap or early-session move without a clear fundamental driver to sustain momentum into the close. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a pharmaceutical stock. With 225 minutes remaining, there is time for either continuation or mean reversion, but the absence of a catalyst makes high-conviction continuation unlikely.
?May 12, 11:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.86% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly favorable for large-cap pharma/biotech names like ABBV. With 240 minutes remaining and no clear fundamental driver, there is meaningful risk of mean reversion or profit-taking into the close, making continuation uncertain.
?May 12, 11:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.43% today with no accompanying news headlines to explain the catalyst, suggesting the move may be driven by sector rotation, options activity, or a gap that lacks fundamental support. With 255 minutes remaining there is time for continuation, but without a clear identifiable catalyst the probability of sustained momentum is moderate at best. The macro context (elevated inflation expectations) is not directly favorable for large-cap pharma, and absent a news driver, mean reversion risk is meaningful after a move of this magnitude.
?May 12, 11:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.85% with no identifiable headline catalyst visible in the recent news feed, suggesting this may be a gap-up or early momentum move without a clear fundamental driver sustaining it. The macro context references elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 270 minutes remaining, there is ample time for either continuation or mean reversion, but the absence of a confirmed catalyst makes high-confidence continuation unlikely.
?May 12, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.49% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a temporary liquidity-driven spike. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 285 minutes remaining there is time for a continuation, but without a clear catalyst, the move is more likely to partially mean-revert or consolidate near current levels rather than extend meaningfully into the close.
?May 12, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.24% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting the move may be driven by broader market or sector flows rather than a company-specific development. The macro context flags elevated 5-year inflation expectations (T5YIE at 1.9σ above trend), which is more relevant to gold, energy, and TIPS sectors than large-cap pharma like ABBV. With 300 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear fundamental catalyst makes sustained continuation uncertain.

← Back to dashboard